“핵산(cDNA) 및 그에 의해 코딩되는 단백질에 관한 출원발명이 특정적이고 실질적이며 신뢰할만한 유용성이 없으므로 산업상 이용가능성이 없는 발명 또는 기재불비에 해당하여 특허를 받을 수 없다고 판단한 사례: 특허법원 2008. 9. 26. 선고 2007허5116 판결”
Woodard, Larry N., The West German Smorgasbord Approach to IntellectualProperty Protection of Computer Software, 15 J. Marshall J. Computer &Info. L. 883 (1997).
Westerlund, Li, Biotech Patents: Equivalency and Exclusion under Europeanand US Patent Law, Kluwer Law International (2002).
Watson, James, Francis H. C. Crick, Molecular structure of nucleic acids. AStructure for Deoxyribose Nucleic Acid, 171 Nature 737 (1953).
The age of access: the new culture of hypercapitalism, where allof life is a paid-for experience, 소유의 종말, 이희재 편역
Smith, Mary Breen, “An End to Patents? The Human Genome Project versusthe United States Patent and Trademark Office's 1999 UtilityGuidelines”, 73 U. Colo. L. Rev. 747 (2002).
Shimanami, Ry?, The Future of the Patent System, School of Law, EdwardElgar Pub (2013).
Seto, Rowena C., Selling the Pharm: Selling the Pharm: The Risks, Benefits,and Regulation of Biopharmaceuticals, 27 Environs: Envtl, L. & Pol'y J. 443 (2003).
Schulte, Rainer, Patentgesetz. Kommentar, Carl Heymanns verlag, 8.Aufl., 2008.
Scalise, David G. & Daniel Nugent, International Intellectual PropertyProtections for Living Matter: Biotechnology, Multinational Conventionsand the Exception for Agriculture, 27 Case W. Res. J. Int'l L. 83 (1995).
Safrin, Sabrina, Hyperownership in a Time of Biotechnological Promise: TheInternational Conflict to Control the Building Blocks of Life, TheAmerican Journal of International Law Vol.98 No.4 (2004).
Parasidis, Efthimios, Uniform Framework for Patent Eligibility, 85 Tul. L. Rev. 323 (2010).
Olsen, Byron V., The Biotechnology Balancing Act: Patents for GeneFragments, and Licensing the “Useful Arts”, 7 Alb. L.J. Sci. & Tech. 295(1996).
Mueller, Janice M., Patent Law, 3rd ed., Aspen (2009).
Miller, Courtney J., Patent Law and Human Genomics, 26 Cap. U. L. Rev. 893(1997).
McJohn, Stephen M., Intellectual Property Examples & Explanations, 4th ed.,Wolters Kluwer Law & Business (2013).
McEniery, Ben, Physicality and the Information Age: A Normative Perspectiveon the Patent Eligibility of Non-Physical Methods, 10 Chi.-Kent J. Intell. Prop. 106 (2010).
McCabe, Kevin W., The January 1999 Review of Article 27 of the TRIPsAgreement: Diverging Views of Developed and Developing CountriesToward the Patentability of Biotechnology, 6 J. Intell. Prop. L. 41 (1998).
McBride, Scott M., Patentability of Human Genes: Our Patent System CanAddress the Issues without Modification, 85 Marq. L. Rev. 511 (2001).
Machlup, Fritz, The Production and Distribution of Knowledge in the UnitedStates, Princeton University Press (1962).
Levang, Bradley J., Evaluating the Use of Patent Pools For Biotechnology: ARefutation to the USPTO White Paper Concerning Biotechnology PatentPool, 19 Santa Clara Computer & High Tech L. J. 229 (2002).
Lemley, Mark A., Ex Ante Versus Ex Post Justifications for IntellectualProperty, 71 U. Chi. L. Rev. 129 (2004).
Lazewski, Marek & S. Lazewska & Son, What is technical in Europe?Patentability of data processing, Vth Common Seminar on IndustrialProperty organized by the Polish Group of AIPPI and German Group ofAIPPI (2002. 11)Lee, Nari, Patent Eligible Subject Matter Reconfiguration and the Emergenceof Proprietarian Norms - The Patent Eligibility of Business Methods, 45IDEA 321 (2004).
Kitch, Edmund W., The Nature and Function of the Patent System, 20 J. L. &Eco. 265 (1977).
Kieff, F. Scott, Property Rights and Property Rules for CommercializingInventions, 85 Minn. L. Rev. 697 (2001).
Kane, Elieen M., Splitting the gene: DNA Patents and the Genetic Code, 71Tenn. L. Rev. 707 (2004).
Holman, Molly A. & Stephen R. Munzer, Intellectual Property Rights in Genesand Gene Fragments: A Registration Solution for Expresed SequenceTags, 85 Iowa L. Rev. 735 (2000).
Heller, Michael A. & Rebecca S. Eisenberg, Can Patents Deter Innovation?The Anticommons in Biomedical Research, Science Vol.280 No.5364(1998).
Harrison, Jeffrey L., Law and Economics, Thomson West (2003).
Hardin, Garrett, The Tragedy of Commons, Science Vol.162 No.3859 (1968).
Hacon, Richard & Jochen Pagenberg, Concise European Patent Law, 2nd ed.,Kluwer Law International (2009).
Goldstein, Paul & Anthony R. Reese, Copyright, Patent, Trademark and RelatedState Doctrines, 6th ed., Foundation Press (2012).
Gold, Richard & Julia Carbone, Myriad Genetics: In the Eye of the PolicyStorm, Genetics in Medicine Vol.12 No.4 (2010. 4).
Gitter, Donna M., International Conflicts over Patenting Human DNASequence in the United States and the European Union: An Argumentfor Compulsory Licensing and A Fair-Use Exemption, 76 N.Y. U. L. Rev. 1623 (2001).
Garris, Joel J., The Case for Patenting Medical Procedures, 22 Am. J. L. andMed. 85 (1996).
Ewing, Lillian, In re Fisher: Denial of patents for ESTs signals deeperproblems in the utility prong for patentability, 8 Minn. J. L. Sci. & Tech. 645 (2007).
Epstein, Micheal A., Modern Intellectual Property, 5th ed., Aspen Publishers(2013).
Eisenberg, Rebecca S., How can you patent genes? , The American Journal ofBioethics Vol.2 No.4 (2002).
ECC, Proposal for a Directive of the European Parliament and the Council onthe patentability of computer-implemented inventions, Brussels (2002).
E.P.O., Patents for software? European law and practice (2008).
Dutfield, Graham, DNA Patenting: Implications for Public Health Research,Bulletin of the World Health Organization Vol.84 No.5 (2006).
Demaine, Linda J. & Aaron Xavier Fellmeth, Reinventing the Double Helix: ANovel and Nonobvious Reconceptualization of the Biotechnology Patent,55 Stan. L. Rev. 303 (2002).
Dastgheib-Vinarov, Sara, A Higher Nonobviousness Standard for GenePatents: Protecting Biomedical Research from the Big Chill, 4 Marq. Intell. Prop. L. Rev. 143 (2000).
Cummings, Michael, Human Heredity: Principles and Issues Paperback, 10thed., BrooksCole (2013).
Cotter, Thomas F., Burkean Perspective on Patent Eligibility, 22 BerkeleyTech. L.J. 855 (2007).
Cohen, Julie E. & Mark A Lemley, Patent Scope and Innovation in theSoftware Industry, 89 Calif. L. Rev. 1 (2001).
Clark, David P. & Nanette Pazdernik, Biotechnology: Applying the GeneticRevolution, Elsevier Science (2008).
Chambers, Jasemine, Patent eligibility of biotechnological inventions in theUnited States, Europe, and Japan: how much patent policy is publicpolicy? , 34 Geo. Wash. Int'l L. Rev. 223 (2002).
Butler, Declan & Sally Goodman, French Researchers Take a Stand AgainstCancer Gene Patent, 413 Nature 95 (2001).
Busse, Rudolf / Keukenschrijver, Alfred, Patentgesetz. Kommentar, De Gruyter,7.Aufl., 2013.
Brougher, Joanna T., Intellectual Property and Health Technologies: BalancingInnovation and the Public's Health, Springer (2013).